Long term clinical outcome of treatment for chronic hepatitis C in patients with advanced fibrosis

Long term clinical outcome of treatment for chronic hepatitis C in patients with advanced fibrosis - outcome of therapy for HCV in advanced fibrosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34894

Enrollment

Registered

2010-03-23

Start date

2010-09-18

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic liver disease chronic viral hepatitis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - history of chronic Hepatitis C - Interferon based antiviral treatment for chronic hepatitis C between 1990 en 2003 - biopsy-proven advanced liver fibrosis (metavir score F3-F4)

Exclusion criteria

Exclusion criteria: - HIV infection - chronic hepatitis B infection - secondary liver disease

Design outcomes

Primary

Measure	Time frame
- hepatcellular carcinoma - liver failure: Ascites/encephalopathy/jaundice/variceal bleed - death - new onset Diabetes Mellitus	—

Secondary

Measure	Time frame
- Biochemical results: ALT/AST/albumin/bilirubin/creatinine/glucose/insulin/HbA1c - Hemological results: platelet count/prothrombin time - Virology: viral load - Ultrasound: spleen size - Fibroscan results: liver stiffness	—

Countries

Netherlands

Outcome results